TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00756067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
Study: NCT03828968

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bladder scan
Description: Measurement of vesical volume by bladder scan
Study: NCT00097227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Study: NCT00704769

Intervention type: DRUG
Intervention: Desloratadine (assigned by investigator as part of normal practice)
Description: Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
Study: NCT03874819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium cut-off dialyzer
Description: Treatment using a Medium Cut-Off Dialyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: Treatment using a high-flux dialyzer
Study: NCT00575419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: * Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day
Study: NCT04527536

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatal hyperbilirubinemia
Description: Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatal hyperbilirubinemia
Description: Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
Study: NCT01400958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nuvigil®
Description: Nuvigil® 150 mg/day x 42 days THEN, No More Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x 42 days; THEN, No More Placebo
Study: NCT01118754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspention; QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspention; QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspention; QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspension; QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 ophthalmic suspension vehicle
Description: ophthalmic suspension vehicle; QID
Study: NCT04527536

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatal hyperbilirubinemia
Description: Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
Study: NCT01890733

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system
Study: NCT00715949

Intervention type: OTHER
Intervention: Immediate Post-concussion Assessment and Cognitive Testing
Description: ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
Study: NCT01406730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 16 week of periodized progressive running exercise 2-4 times/week
Study: NCT03053713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet pattern
Description: Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Habitual diet (control)
Description: Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
Study: NCT02790450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: 1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
Study: NCT00424099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Telephone Intervention
Description: Call from study nurse 3 times weekly to ask about side effects and other symptoms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nursing Telephone Intervention
Description: Call from study nurse 3 times weekly to ask about side effects and other symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non NTI
Description: Non NTI are calls from research staff 3 times weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non NTI
Description: Non NTI are calls from research staff 3 times weekly.
Study: NCT03377452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)
Description: Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive sleep apnea education control
Description: Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
Study: NCT03082066

Intervention type: OTHER
Intervention: CT or MRI scan
Description: CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter

Intervention type: OTHER
Intervention: CT or MRI scan
Description: CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
Study: NCT01138254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSTM TY101 FIR emitter (Far infrared therapy)
Description: A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: no intervention
Study: NCT04362046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic uterine resection
Description: Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications.
Study: NCT04354389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 4.5 mg b.i.d
Study: NCT03058289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.
Study: NCT00789594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laboratory monitoring alerts
Description: laboratory monitoring alerts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laboratory monitoring alerts
Description: laboratory monitoring alerts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Result management module
Description: Result management module
Study: NCT02884193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brief Cooling
Description: Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
Study: NCT04354389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q.d. or b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 4.5 mg q.d.
Study: NCT00986375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group (ACG)
Description: Patients in the ACG will get an interactive computerized standard program
Study: NCT04393389

Intervention type: DEVICE
Intervention: AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
Description: All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
Study: NCT00789594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Result management module
Description: Result management module
Study: NCT00429338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AIR-MRSI
Description: 3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFC-MRSI
Description: 3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
Study: NCT02884193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Cold
Description: Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Ice Bag
Description: Placebo application through an ice bag empty.
Study: NCT04254575

Intervention type: OTHER
Intervention: None, observational study only (no interventions)
Description: None, observational study only (no interventions)
Study: NCT00172003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT04115891

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety scale
Description: Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety scale
Description: Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain scale - 1
Description: Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scale - 1
Description: Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain scale - 2
Description: Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scale - 2
Description: Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: lavender oil inhalation in a separate room for 3 minutes prior to interventions
Study: NCT01320527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutriceutical formulation
Description: Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A mixture of 6 vitamins and nutriceuticals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A mixture of 6 vitamins and nutriceuticals
Study: NCT01345825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
Study: NCT02407236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo will be administered as intravenous infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IV
Description: Placebo will be administered as intravenous infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo SC
Description: Placebo will be administered Subcutaneously.
Study: NCT00370942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C A
Description: A=45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C B
Description: B=30 mg
Study: NCT02407236

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo SC
Description: Placebo will be administered Subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered Subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab IV
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
Study: NCT00370942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C C
Description: C=25 mg
Study: NCT02628106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-PGE1
Description: all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
Study: NCT02407236

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.
Study: NCT00284258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11 and TS-1
Description: TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11, 5-FU and l-LV
Description: Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
Study: NCT01762592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine (124I) Girentuximab
Description: i.v.
Study: NCT03330093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health in Preschoolers
Description: In-person, family-based behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Safety Intervention
Description: In-person, family-based behavioral intervention
Study: NCT03497390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMERALD intervention
Description: EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care without any workshop or program
Study: NCT03081819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH003
Description: Herbal medicine for cancer treatment
Study: NCT02080585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity advice.
Description: Subjects receive advice regarding physical activities.
Study: NCT00649805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose applesauce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose applesauce
Study: NCT04379375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nudge
Description: Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
Study: NCT05759260

Intervention type: OTHER
Intervention: Observation
Description: Observation

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT04773431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation
Description: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
Study: NCT01183598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: maintenance dose
Study: NCT03956992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth gel
Description: Stop using the mouth gel
Study: NCT00785590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study: NCT04789629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: 3 session per week laser with exercises

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: 3 session per week laser with exercises